Bracco Imaging SpA manufactures and develops diagnostic imaging solutions for public and private hospitals, imaging centers and private practices. The firm's services include radiology, X-ray imaging, magnetic resonance imaging and ultrasound applications. The company was founded in 1985 and is headquartered in Milan, Italy.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Cell>Point LLC develops intra-nuclear universal molecular imaging and therapeutic products for the diagnosis, staging, treatment and post therapy assessment of cancer, cardiovascular diseases, and infectious diseases. It focuses on chelation based metabolic imaging and intra-nuclear target specific therapy for oncology, cardiology including stroke, diabetes, neuroendocrine, and ischemic based diseases. The company was founded by Greg Russel Colip, Terry Allen Colip and Jerry Bryant in 2001 and is headquartered in Centennial, CO.

Nanjing Legend Biotechnology Co., Ltd. is a private company headquartered in Nanjing, China, that develops tumor cell immunotherapies.

Diadem Biotherapeutics, Inc. is an American company located in Torrance, CA, that operates biotechnology company that focuses on creating bio-therapeutically materials produced using organic means. It was founded in 2019 by Mickey Joseph Pentecost, he has been the CEO since that date.

IGF Oncology is a biotech company developing targeted anti-cancer chemotherapy drugs with better efficacy and lower side effects and, as compared to existing chemotherapy treatments. Their lead drug, IGF-MTX, targets the deadly blood cancer MDS, and is currently in clinical trials at the Mayo Clinic, and the results so far are excellent.

The University of Iowa Research Foundation (UIRF) - a 501C3 corporation - commercializes University of Iowa developed technologies and inventions through licensing and new venture formation, and manages the subsequent revenue stream.

Develops oncology immunotherapies for applications in the diagnosis and treatment of cancer

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. The company is committed to developing best-in-class protein therapeutics for the treatment of cancer, autoimmune, and inflammatory diseases. Zymeworks' approach combines proprietary molecular modeling and simulation software with high-performance computing to create an environment for in silico experimentation and predictive protein optimization. Using this approach Zymeworks has developed multiple platform technologies to advance the field of biologics drug discovery and optimization. It was founded in 2004 and headquartered in Vancouver, British Columbia.

Elucida Oncology focuses on transforming outcomes for patients with primary solid tumors and metastatic cancer. The company utilizes the novel target or clear capabilities of its ultra-small C-Dot cancer-targeting particle platform across diagnostic imaging, surgical, and a wide range of therapeutic applications.

CART Medical Technologies, Ltd. is a high-tech company specializing in the development and application of new technologies for immune cell therapy. It has a 2,200 square meter GMP laboratory and research and development laboratory.

FluoGuide A/S is a clinical stage biotechnology company, which engages in the development of drugs used for the improvement of surgical outcomes by making cancer fluorescent. Its technology includes uPAR, fluorescent guidance to surgical oncologists, and photothermal treatment. The company was founded by Andreas Kjaer on January 30, 2018 and is headquartered in Copenhagen, Denmark.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.